Dutrebis FDA Approval History
FDA Approved: Yes (Discontinued) (First approved February 6, 2015)
Brand name: Dutrebis
Generic name: lamivudine and raltegravir
Dosage form: Tablets
Company: Merck
Treatment for: HIV Infection
Dutrebis (lamivudine and raltegravir) is a fixed-dose combination of a nucleoside analog reverse transcriptase inhibitor and an integrase strand transfer inhibitor for the treatment of HIV-1 infection.
Dutrebis is NOT commercially available in the U.S.
Development timeline for Dutrebis
| Date | Article |
|---|---|
| Feb 10, 2015 | Approval FDA Approves Dutrebis (lamivudine and raltegravir) for HIV-1 Infection |
| Jun 24, 2014 | FDA Accepts Merck’s NDA for Fixed-Dose Combination of Raltegravir with Lamivudine |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.